We thus propose that overexpression of TDRD1, observed by us and others in 100% of TMPRSS2:ERG-positive prostate tumors, makes TDRD1 a promising target for immunotherapy of ERG rearrangement-positive prostate cancer. Here, TDRD1 is linked to prostate neoplasm.